Life sciences briefing: Friday, Aug. 31, 2007
Featured companies: Aryx Therapeutics, FlowCardia, Graftcath
FlowCardia raises $30M for artery roto-rooters — Sunnyvale, Calif.-based FlowCardia, a medical-device maker building catheter systems that bore holes in blood clots, raised $30 million in a third funding round. Investors included Gilde Healthcare Partners, Life Sciences Partners, Hambrecht & Quist Capital Management, New Science Ventures, Frazier Healthcare Ventures, JP Morgan Partners, Pappas Ventures, Rockport Venture Partners and Gold Hill Capital. The funding is intended to speed commercialization of the company’s… Continue Reading
The FDA’s big personalized-medicine push
(UPDATED: See below.)
Personalized medicine — the idea that doctors will one day tailor your medical care based on your genetic profile — has been a long time coming, as I’ve previously written. As it turns out, that’s no fault of the Food and Drug Administration, which has emerged as one of the biggest fans of the concept. Yet the FDA is now pushing ahead with efforts to pair drugs with genetic tests in a way that… Continue Reading